SWX:NOVNPharmaceuticals
Should Multiple Sclerosis Trial Win Require Action From Novartis (SWX:NOVN) Investors?
Novartis reported Phase III REMODEL-1/-2 data showing that remibrutinib reduced annualized relapse rates and MRI lesions versus teriflunomide in adults with relapsing multiple sclerosis, with a favorable safety profile and plans to seek global regulatory approval.
The remibrutinib readout adds another late-stage asset alongside existing priority brands and reinforces Novartis' focus on high-value immunology and neuroscience therapies that can support its broader push for higher quality...